# **PATENT**

<u>heet</u> 1 <u>of</u> 3

FORM PTO-1449		IS D	EDAL	OTA 4E	NIT O	5.00	A 48 41	- חרב	ATTY. DC	CKET	NO.	SERIAL N	10.		<del></del>		
(Modified) D			epaf Nt Ai							M01846A			08/893,080				
1/01/6	INPORMA:	TION	DISC	CLOS	URE					APPLICANT							
SEP 1 1 19	CTATEMEN	VT BY	APP	LICA	NT					Alan M. Warshawsky et al							
SEP 1 1	lse se eral	shee	ets if ı	nece	ssan	()				EILING DATE COOLD							
TRADEM	RICE .								July 15,	1997		ļ	16 7	94			
TRADEM											U.S. PATENT DOCUMENTS						
EXAMINER INITIALS	•	DOCUMENT NUMBER							DATE		NAME	CLASS	SUBCLASS	FILING D			
1.16	A1	4	6	8	1	9	6	6	7/21/87		Donald et al	OD CO	000000	711110	MITTLE		
B.K.	A2	4	5	9	9	3	6	1	7/8/86		Dickens et al						
1.16	A3	4	8	8	5	2	8	3	12/5/89		Broadhurst et al						
BK	A4	4	7	7	1	0	3	8	9/13/88		Wolanin et al						
D.K.	A5	5	3	0	4	5	4	9	4/19/94		Broadhurst et al						
B.K.	A6	5	3	1	0	7	6	3	5/10/94		Campion et al						
sy.	A7	4	9	3	5	4	0	4	6/19/90		Hunter et al				**		
Byli	A8	5	2	5	2	5	6	0	10/12/93		Myers et al						
D.K.	A9	5	3	6	2	7	5	0	11/8/94		Rosini et al						
DK.	A10	5	3	0	0	5	0	1	4/5/94		Porter et al		<u>.</u> .				
13.K-	A11	5	4	2	4	4	2	5	6/13/95		Flynn et al						
15 Kr	A12	5	4	2	8	1	5	8	6/27/95		Warshawsky et al						
13.16.	A13	5	4	5	7	1	9	6	10/10/95		Warshawsky et al						
DK.	A14	5	4	3	0	1	4	5	7/4/95		Flynn et al						
B16.	A15	5	4	2	0	2	7	1	5/30/95		Warshawsky et al						
BK.	A16	5	2	3	8	9	3	2	8/24/93		Flynn et al	ļ <u>.</u>					
D.K.	A17	5	3	8	9	6	2	8	2/14/95		Flynn et al						
11/6	A18	5	4	5	5	2	4	2	10/3/95		Warshawsky et al						
1316	A19	5	3	6	6	9	7	3	11/22/94		Flynn et al						
B.K.	A20	5	2	3	9	0	7	8	8/24/93		Galardy et al		-				
BK.	A21	5	5	0	4	2	1	2	4/2/96		de Solmes et al						
EXAMINER	•	Γ.					_FC	)KEI	GN PATEN	ו טטפ	CUMENIS			TRANSL	ATION		
INMALS	B1	9	DO	CUM 1	ENT 3	NUM 2	BER 8	9	DATE 5/18/95	wo	COUNTRY	CLASS	SUBCLASS	YES	NO		
13/1	B2	0	5	3	4	3	6	3	3/31/93	EP							
10.1/	B3	0	4	8	9	5	7	9	6/10/92	EP							
10 70	B4	0	6	2	1	2	7	0	10/26/94	Eρ							
13 ·/C ·	B5	0	2	3	6	8	7	2	9/16/87	EP							
N.K.	125	Ľ	<u> </u>	تــــــــــــــــــــــــــــــــــــــ	<u> </u>	<u> </u>	<u>Ľ</u> _		// IG/G/		i						
EXAMINER	15	7 14	N	/	2		1			DATE (	CONSIDERED	2/26	104				
conformance an	nd not cons ) It <b>m(s) ha</b>	idere v b	ed. li <del>een</del> j	nclud pr vi	de co loust	DDY C	of this	form	n with next c	ommu	ace with MPEP 609. Counication to applicant to the applicant of the applicant to the applic	t.			oples		

\_ \_ \_ \_ ,

ATTY. DOCKET NO. SERIAL NO. U.S. DEPARTMENT OF COMMERCE FORM PTO-1449 PATENT AND TRADEMARK OFFICE (Modified) M01846A 08/893,080 INFORMATION DISCLOSURE APPLICANT STATEMENT BY APPLICANT Alan M. Warshawsky et al (Use several sheets if necessary) FILING DATE GROUP 1624 July 15, 1997 **U.S. PATENT DOCUMENTS** FILING DATE IF **EXAMINER** DOCUMENT NUMBER DATE NAME **CLASS** SUBCLASS **APPRORIATE** INITIALS **FOREIGN PATENT DOCUMENTS EXAMINER** TRANSLATION DATE COUNTRY INITIALS DOCUMENT NUMBER **CLASS** SUBCLASS wo **B6** 6 3 6 2 2 11/21/96 5/29/97 wo **B7** 9 7 9 0 7 5 1 WO **B8** 7 0 8 5/15/97 8 **OTHER DOCUMENTS EXAMINER** AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC. INITIALS C1 McCachren, S.S. Arthritis Rheum. 34, pp 1085-1093 (1991) C2 Emonard, H. et al, Cell Molec. Biol. 36, pp 131-153 (1990) **C3** Birkedal-Hansen, H., J. Oral Pathol. 17, pp 445-451 (1988) C4 Matrisian, L.M., <u>Trends Genet</u>. 6, pp 121-125 (1990) **C5** Murphy, G.J.P. et al, FEBS Lett. 289, pp 4-7 (1991 **C6** Matrisian, L.M., Bioessays 14, pp 455-463 (1992) **C7** Swhwartz, G.K. et al, <u>Cancer</u> 73, pp 22-27 (1994) Bernhard, E.J. et al, Proc. Natl. Acad. Sci. 91, pp 4293-4597 (1994) C9 Zucker, S. et al, Cancer Res. 53, pp 140-146 (1993) C10 Chirivi, R.G.S. et al, <u>Int. J. Cancer</u> 58, pp 460-464 (1994) C11 Montgomery, A.M.P. et al, Cancer Res. 54, pp 5467-5473 (1994) C12 Hasty, K.A. et al, Arthr. Rheum. 33, pp 388-397 (1990) C13 Murphy, G. et al, Biochem. J. 248, pp 265-268 (1987) C14 Gearing, A.J.H. et al, Nature 370, pp 555-557 (1994) C15 Mohler, K.M. et al, Nature 370, pp 218-220 (1994) C16 McGreehan, G.M. et al, Nature 370, pp 558-561 (1994)

EXAMINER	Such Kill	DATE CONSIDERED	2/26/04
		· · · ·	

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Note: Ast risk (\*) it m(s) hav been pr viously cited in a related application(s) lither by th applicant r by th USPTO and ther for copi s of the r fer nee(s) ar not being submitted.

# **PATENT**

<u>Sheet</u> 3 <u>of</u> 3

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE	ATTY. DOCKET NO.	SERIAL NO.
(Modified)	PATENT AND TRADEMARK OFFICE	M01846A	08/893,080
	ORMATION DISCLOSURE	APPLICANT	
ST	ATEMENT BY APPLICANT	Alan M. Warshawsky	
(Use :	several sheets if necessary)	FILING DATE	GROUP
		July 15, 1997	1624

### **FOREIGN PATENT DOCUMENTS**

EXAMINER INITIALS	•			DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSI YES	ATION NO
B·K.		В9	9	7	1	2	9	0	2	4/10/97	wo				
N.Ki		B10	9	7	1	2	8	6	1	4/10/97	wo				
D.K.		B11	9	6	3	5	7	1	4	11/14/96	wo				
1.K.		B12	9	6	6	5	7	1	2	11/14/96	wo				
N.K.		B13	9	6	3	5	7	1	1	11/14/96	wo				
B.K.		B14	9	6	3	5	6	8	7	11/14/96	wo				

## OTHER DOCUMENTS

EXAMINER INITIALS	•	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
1.16.	C17	Wahl, R.C. et al, Annual Reports in Medicinal Chemistry 25, pp 177-184 (1990)
D.K.	C18	Hennney, A.m., et al, <u>Proc. Natl. Acad. Sci.</u> 88, pp 8154-8158 (1991)
B'K.	C19	Burns, F.R. et al, Invest. Opthalmol. and Visual Sci. 30, No. 7 pp 1569-1575 (1989)
D.K.	C20	Overall, C.M. et al, J. Periodontal Res. 22, pp 81-88 (1987)
D.K.	C21	Miyazaki, K. et al, <u>Nature</u> 362, pp 839-841 (1993)
	C22	Beckett, R.P. et al, "Recent advances in matrix metalloproteinase inhibitor research" <u>DDT</u> Vol. 1, No. 1, January, 1996, pp 16-26
D.K. B.K.	C23	Blanchard et al, "Reevaluation of the Absorption of Carbenoxolone Using an In Situ Rat Intestinal Techinque", Journ. Pharmaceutical Sci., Vol. 79, No. 5, May, 1990 pp 411-414
B.K.	C24	Davies, B. et al, "A Synthetic Matrix Metalloproteinase Inhibitor Decreases Tomor Burden", Cancer Research 53, May 1, 1993, pp 2087-2091
B.K.	C25	Hodgson, John, "Remodeling MMPIs", Bio/Technology Vol. 13, June 1995 pp 554-557
A.K.	C26	Chapman, K.T., "Inhibition of Matrix Metalloproteinases", J. Med. Chem. 1993, 36, pp 4293-4301
D.K.	C27	Beeley N.RA, "Inhibitors of Matrix Metalloproteinases (MMP's)", Curr. Opin, Ther. Patents (1994) 4(1), pp 7-16
D:K· D:K·	C28	Baxter, Andrew D. et al, "A Novel Series of Matrix Metalloproteinase Inhibitors for the Treatment of Inflammatory Disorders", Bioorganic & Medicinal Chem. Letters, Vol. 7, No. 7 pp 897-902, (1997)
1.10	C29	CA, Issue 3, pp 16, 126:60361y (1997)

EXAMINER	Buch XIII	DATE CONSIDERED	2/26/04	
			T T T T T T T T T T T T T T T T T T T	

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Not: Ast risk (\*) it m(s) hav been pr viously cited in a r lated application(s) lither by the applicant r by th USPTO and th r for copi s

of the r ferenc (s) ar not being submitted.

Sheet

ORM PTO-14 Modified)	49 .			EPAF								NO.	SERIAL I			•	
(Modified) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE								_	rict	14101940	M01846A 08/893,080 APPLICANT						
		TATEMEN					01	P	E)	1		shawsky, et al.					
	(Use	several	shee	ets if r	nece				7	FILING D		snawsky, et al.	GROUP	,	<del>-</del>		
					- (	_ S	EP 0	8 1	398	7-15-97			1205	1624			
			-		· '				~@	<b>}</b>	-		1		_		
EXAMINER	•	T	т				TRA	DEM	W.S	PATENT D	ocu	IMENTS		<u> </u>	FILING [	DATE II	
INITIALS	_		<del> </del>	DC T	CUM	1ENT				DATE		NAME	CLASS	SUBCLASS	APPRORIATE		
			⊢	<u> </u>	<del> </del>				-								
		-	├			_	-	_	-								
<del> </del>		<del> </del>	┢		$\vdash$		-	<u> </u>									
		L	L		<u> </u>	l	L	<u> </u>	l				1	]			
TVA & AINIED			T					FC	REI	GN PATEN	T DO	CUMENTS		<del>,</del>	T - 70 1 1 10		
EXAMINER INITIALS		ļ		_	<del></del>	1ENT		_		DATE				SUBCLASS	TRANSL YES	AIION NO	
13.K.		B.15	9	6	0	6	8	9	0	9/88	WO					<u> </u>	
B.K.		B.16	9	6	1	1	2	0	9	4/96	WO						
B.K.		B.17	9	6	2	9	3	1	3	9/96	wo	)				<u> </u>	
			<u> </u>	<u> </u>	<u> </u>		l						<u></u>	<u></u>		<u> </u>	
									(	OTHER DO	CUM	ENTS					
EXAMINER INITIALS	•									AUTHOR,	TITLE,	DATE, PERTINENT P	AGES, ETC.	· · · · · · · · · · · · · · · · · · ·			
B:K.		C.30	D	erwe	ent A	Abs	tract	96	-035			04, WPI Datab		046217			
1.16.		C.31	Bı	ırkh	old	er, E	E.A.	, Bi	oorg	Med Che	em L	ett, vol 3, no 2,	1993, p 23	1-234, XP0	020462	16	
<u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>			$\vdash$														
			<del>                                     </del>				<del></del>										
														· · · · · · · · · · · · · · · · · · ·		_	
			1														
														··· •4 · · • ·	*		
		<u> </u>	_														
	L		L		•												
A & AIR 155				_	0.		//	,						,			
AMINER	//	Jun	N	<u> </u>	<u>K</u>	1					DATE	CONSIDERED	2/26/0	24			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Not: Ast risk (\*) item(s) hav been pr viously cited in a r lated application(s) ith r by th applicant or by th USPTO and th refor copies of th r ferenc (s) ar not being submitted.